MAPK8 and breast carcinoma: In terms of therapeutic interventions for HER2-inhibitor resistant breast cancers, we have provided evidence that targeting JNK with the pan-JNK inhibitor SP600125 was effective in delaying tumor growth in the xenograft JIMT-1 mammary tumor model system.